Evidence map›Paper›PMID 20972805›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2011

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.

Steven M Grunberg, David Warr, Richard J Gralla, Bernardo L Rapoport, Paul J Hesketh, Karin Jordan, Birgitte T Espersen

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02407600 phase2unknown statusnot on this mapstarted 2015, after this paper: background citation

Phase II, Double-blind, Placebo-controlled, Crossover Study Evaluating a 5HT3 Antagonist Plus Dexamethasone With or Without Fosaprepitant in Patients With Advanced NSCLC Receiving Carboplatin Based Chemotherapy

TypeinterventionalSponsorAjeet GajraRan2015 to 2018Enrolled150ConditionsNon-small Cell Lung Cancer, Vomiting, Nausea, EmesisArmsFOSAPREPITANT (Emend), Placebo
NCT03606369 phase2 / phase3unknown statusnot on this mapstarted 2015, after this paper: background citation

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

TypeinterventionalSponsorInstituto Nacional de Cancerologia de MexicoRan2015 to 2020Enrolled560ConditionsBreast Neoplasm, Antineoplastic Agents, Antiemetics, Quality of LifeArmsPalonosetron, Ondansetron
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. SEOM clinical guideline emesis (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Guideline
  3. SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013
    Guideline
  4. A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. The evolving landscape of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: inspiration from cisplatin-based antiemetic and non-antiemetic trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  18. Review
  19. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Review
  20. Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Steven M GrunbergDivision of Hematology/Oncology, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E214, Burlington, VT 05405, USA. Steven.Grunberg@uvm.edu
David Warr
Richard J Gralla
Bernardo L Rapoport
Paul J Hesketh
Karin Jordan
Birgitte T Espersen

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiemetic drug development can follow the same logical path as antineoplastic drug development from appropriate preclinical models through Phase I, Phase II, and Phase III testing. However, due to the marked success of antiemetic therapy over the last 25 years, placebo antiemetic treatment against highly or moderately emetogenic chemotherapy is not acceptable. Promising antiemetic agents therefore rapidly reach Phase III testing, where they are substituted into or added to effective and accepted regimens. One challenge of antiemetic drug development is determining whether substitution is indeed acceptable or whether prior regimens must be maintained intact as a basis for further antiemetic drug development. An additional challenge is the classification of emetogenic level of new antineoplastic agents. Accurate reporting of emetogenicity of such antineoplastic agents in the absence of preventive antiemetic treatment may not be available. However, at the 2009 Multinational Association of Supportive Care in Cancer (MASCC)/European Society of Medical Oncology (ESMO) Consensus Conference, an expert panel used best available data to establish rankings of emetogenicity. Oral chemotherapeutic agents are ranked separately from intravenous agents, recognizing intrinsic differences in emetogenicity as well as differing schedules of administration. Since oral chemotherapeutic agents are often administered in extended regimens, the distinction between acute and delayed emesis is less clear, and cumulative emesis must be considered. As control of vomiting has improved, attention has shifted to control of nausea, a related but distinct and equally important problem. Additional efforts will be necessary to understand mechanisms of nausea and to identify optimal remedies.

Indexed as

AntiemeticsAntineoplastic AgentsClinical Trials as TopicDexamethasoneDrug Administration RoutesDrug Administration ScheduleHumansNauseaNeurokinin-1 Receptor AntagonistsPractice Guidelines as TopicSerotonin AntagonistsVomitingAntiemeticsAntineoplastic AgentsDexamethasoneNeurokinin-1 Receptor AntagonistsSerotonin Antagonists

Identifiers

PMID20972805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.